论文部分内容阅读
非典型鳞状细胞(atypical squamous cells,ASC)自1943年被首次提出,历经1988,1991和2001年TBS(the Bethesda System)三版修订,非典型鳞状细胞被分为意义不明确的不典型鳞状细胞(ASC of undetermined significance,ASC-US)和不除外高度上皮内病变的不典型鳞状细胞[ASC cannot exclude high-grade squamous intraepithelial lesion(HSIL),又称为ASC-H],这两个术语已得到临床实践证实,用其作为诊断分类明显提高了宫颈巴氏细胞学临床使用性。诊断为ASC-US和ASC-H的患者行高危型人乳头状瘤病毒(high-risk types of human papillomavirus,HR HPV)检测后分组管理,使后续的处理及治疗更加人性化,提高了宫颈液基薄层细胞学筛查的可靠性,降低了人为的过度治疗,使宫颈细胞学筛查更具科学性、可行性。
The atypical squamous cells (ASC) were first proposed in 1943 and revised by the third edition of TBS (the Bethesda System) in 1988, 1991 and 2001. The atypical squamous cells are classified into atypical squamous cells ASC of undetermined significance (ASC-US), and ASC can not exclude high-grade squamous intraepithelial lesion (HSIL), also known as ASC-H], both A term has been clinically proven, using it as a diagnostic classification significantly improve the clinical use of cervical Papanocytology. Patients diagnosed with ASC-US and ASC-H underwent high-risk types of human papillomavirus (HR HPV) test after group management, so that the follow-up treatment and treatment more humane, increased cervical fluid The reliability of basal cytology screening reduces the need for artificial over-treatment and makes cervical cytology screening more scientific and viable.